NCT01923207已完成1 期
A Phase 1, Double-Blind, Single Ascending Dose Study to Assess Safety, Tolerability and Pharmacokinetics of DX-2930 (Recombinant Fully Human Antibody Inhibitor of Plasma Kallikrein) in Healthy Subjects
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- Shire
- 入组人数
- 32
- 试验地点
- 1
- 主要终点
- Proportion of subjects with adverse events
研究概览
简要总结
The purpose of this study is to assess the safety and tolerability of the study drug (DX-2930) administered subcutaneously in healthy subjects. Subjects will be randomized to receive DX-2930 or placebo.
详细描述
Approximately 32 healthy subjects will be randomized to receive DX-2930 or placebo.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 55 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Male or female subjects who are 18 to 55 years of age, inclusive.
- •Willing and able to read, understand, and sign an informed consent form.
- •Willing and able to receive subcutaneous injections.
- •Body mass index (BMI) of 18 to 33 kg/m2 with a weight of at least 60 kg for males and at least 50 kg for females, with a maximum weight of 130 kg for any subject.
- •Medically healthy as determined by the investigator via assessment of physical examination, medical history, clinical laboratory tests, vital signs, and electrocardiogram (ECG).
- •Females of childbearing potential must agree to be abstinent or else use any two of the following medically acceptable forms of contraception from the Screening Period through 30 days after the final study visit: condom with spermicidal jelly, diaphragm or cervical cap with spermicidal jelly, or intra-uterine device (IUD). A female whose male partner has had a vasectomy must agree to use one additional form of medically acceptable contraception. Female subjects must agree to practice the above birth control methods for 30 days after the final study visit as a safety precaution.
- •Females of non-childbearing potential, defined as surgically sterile (status post hysterectomy, bilateral oophorectomy, or bilateral tubal ligation) or post-menopausal for at least 12 months (and confirmed with a screening follicle-stimulating hormone (FSH) level in the post-menopausal range), do not require contraception during the study.
- •Males with female partners of childbearing potential must agree to use a highly effective, medically acceptable form of contraception from the screening period through 60 days after the final study visit. All male subjects, including males who are surgically sterile (post vasectomy), must agree to practice the above birth control methods for 60 days from the final study visit as a safety precaution.
排除标准
- •Any active acute or chronic illness at screening.
- •Any history of exposure to a biologic within 90 days prior to dosing.
- •Receipt of any investigational (a non-licensed, non-approved) drug or device within 60 days prior to dosing.
- •Any prior history of exposure to a monoclonal antibody.
- •Pregnant or actively breastfeeding.
- •Any history of substance abuse or dependence.
- •Positive urine drug or alcohol test at screening or Day -1 for amphetamines, benzodiazepines, barbiturates, cocaine, cotinine (detection mechanism for nicotine), marijuana, opiates, phencyclidine or ethanol.
- •Regular use of alcohol within six months prior to the screening visit [more than fourteen units of alcohol per week (1 Unit = 150 mL of wine, 360 mL of beer, or 45 mL of 40% alcohol)].
- •Use of prescription or over-the-counter medication within 14 days prior to administration of study medication, or use of over-the-counter products (dietary or herbal supplements and vitamins) within 14 days prior to administration of study medication.
- •Use of nicotine or nicotine-containing products within the previous three months prior to screening.
- •Subject has any other condition, which in the opinion of the investigator may compromise the safety or compliance or would preclude the subject from successful completion of the study or interfere with the interpretation of the results.
- •Abnormal clinical laboratory values and/or other study assessments such as ECG results deemed to be clinically significant by the investigator.
- •Donation of blood within 60 days preceding Study Day -
- •Serology testing positive for hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV), or human immunodeficiency virus (HIV).
研究组 & 干预措施
placebo
Placebo Comparator
inactive formulation of DX-2930
干预措施: Placebo (Drug)
DX-2930
Experimental
DX-2930 administered by subcutaneous route
干预措施: DX-2930 (Drug)
结局指标
主要结局
Proportion of subjects with adverse events
时间窗: 112 days
次要结局
- DX-2930 plasma level(112 days)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Safety and Tolerability Study of Xisomab 3G3 in Healthy Adult SubjectsThrombosisNCT03097341Aronora, Inc.21
已完成
1 期
Study of ARO-HBV in Normal Adult Volunteers and Patients With Hepatitis B Virus (HBV)Hepatitis BNCT03365947Arrowhead Pharmaceuticals114
已完成
1 期
A Double-Blind, Multiple Ascending Dose Study to Assess Safety, Tolerability and Pharmacokinetics of DX-2930 in Hereditary Angioedema ParticipantsHereditary Angioedema (HAE)NCT02093923Shire38
已完成
1 期
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB100 Administered Orally to Adults With Amyotrophic Lateral SclerosisAmyotrophic Lateral SclerosisNCT03945279Biogen49
已完成
1 期
A Study of LY3532226 in Participants With ObesityObesityNCT06557356Eli Lilly and Company132